IO Biotech (NASDAQ:IOBT – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $12.00 target price on the stock.
IO Biotech Stock Up 1.9 %
NASDAQ:IOBT opened at $0.92 on Wednesday. The company has a fifty day simple moving average of $0.93 and a two-hundred day simple moving average of $1.01. The company has a market cap of $60.41 million, a price-to-earnings ratio of -0.67 and a beta of 0.24. IO Biotech has a 52 week low of $0.66 and a 52 week high of $1.85.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in IOBT. XTX Topco Ltd acquired a new position in IO Biotech in the fourth quarter valued at $26,000. Vontobel Holding Ltd. acquired a new position in IO Biotech in the 4th quarter valued at $30,000. Renaissance Technologies LLC boosted its holdings in IO Biotech by 22.5% in the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company’s stock valued at $109,000 after purchasing an additional 21,800 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of IO Biotech during the 4th quarter worth approximately $249,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of IO Biotech in the 4th quarter valued at approximately $407,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.
About IO Biotech
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
- Five stocks we like better than IO Biotech
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Best Aerospace Stocks Investing
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
